Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study

Stathopoulos,G. P.; Trafalis,D.; Dimitroulis,J.; Athanasiou,A.; Koutantos,J.; Anagnostopoulos,A.

doi:10.3892/ol_00000059

Erlotinib treatment in pretreated patients with non-small cell lung cancer: A Phase II study

Authors:
- G. P. Stathopoulos
- D. Trafalis
- J. Dimitroulis
- A. Athanasiou
- J. Koutantos
- A. Anagnostopoulos
View Affiliations

Affiliations: First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000059
Pages: 335-338

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erlotinib is an oral, small-molecule targeting therapy that inhibits epidermal growth factor tyrosine kinase receptors. Erlotinib has been administered for the treatment of advanced pancreatic cancer and non-small cell lung cancer. In the present trial, erlotinib was administered as second-line monotherapy in pretreated patients with advanced non-small cell lung cancer. Our objectives were to determine response, survival and toxicity. Fifty-four patients pretreated with cisplatin or its analogue-based combinations were evaluated. The disease stage of the patients was IIIB and IV. Thirty-eight patients were male, 16 were female, the median age was 65 years, and the WHO performance status was 0-2. Twenty-five cases were adenocarcinomas, 19 squamous cell carcinomas and 10 were undifferentiated. Erlotinib was administered at a dose of 150 mg daily. In case of intolerable adverse reactions, the dose was either reduced to 100 mg daily or treatment was interrupted for a maximum of two weeks. A partial response was observed in 10 (18.52%) and stable disease in 40 (74.07%) patients. The median time to disease progression was 3 months (95% CI 1.7-10.3), and the median survival was 6 months. Concerning toxicity, 53 patients (98.15%) developed a grade 1-2 skin rash, and 1 (1.85%) grade 3. Diarrhea occurred in 9 (16.67%) patients, nausea and vomiting in 4 (7.41%) and gastritis in 2 (3.70%). The majority of patients tolerated the erlotinib treatment. Of note were the 18.52% response rate and 74.07% stable disease.

View Figures

View References

1	Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol. 23:2445–2459. 2005. View Article : Google Scholar : PubMed/NCBI
2	Jänne PA, Engelman JA and Johnson BE: Epidermal growth factor receptor mutations in non-small cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 23:3227–3234. 2005.PubMed/NCBI
3	Swinson DE, Cox G and O’Byrne KJ: Coexpression of epidermal growth factor receptor with related factors is associated with poor prognosis in non-small cell lung cancer. Br J Cancer. 91:1301–1307. 2004. View Article : Google Scholar
4	Comis RL: The current situation: erlotinib (tarceva) and gefitinib (iressa) in non-small cell lung cancer. Oncologist. 10:467–470. 2005. View Article : Google Scholar : PubMed/NCBI
5	Byoung C-C, Im C-K, Park M-S, et al: Phase II study of erlotinib in advanced non-small cell lung cancer after failure of gefitinib. J Clin Oncol. 25:2528–2533. 2007. View Article : Google Scholar : PubMed/NCBI
6	Shepherd FA, Pereira JR, Ciuleanu T, et al: Erlotinib in previously treated non-small cell lung cancer. N Engl J Med. 353:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
7	Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar
8	Therasse P, Arbuck SG, Eisenhawer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
9	Cohen S: The epidermal growth factor (EGF). Cancer. 51:1787–1791. 1983. View Article : Google Scholar
10	Yarolen Y and Schlessinger J: Epidermal growth factor induces rapid reversible aggregation of the purified epidermal growth factor receptor. Biochemistry. 26:1443–1451. 1987. View Article : Google Scholar : PubMed/NCBI
11	Hsuan JJ: Oncogene regulation by growth factors. Anticancer Res. 13:2521–2522. 1993.PubMed/NCBI
12	Soler C, Beguinot L and Carpenter G: Individual epidermal growth factor receptor autophosphorylation sites do not stringently define association motifs for several SH-2 containing proteins. J Biol Chem. 269:12320–12324. 1994.
13	Voldborg RB, Damstrup L, Spang-Thomsen M, et al: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 8:1197–1206. 1997. View Article : Google Scholar : PubMed/NCBI
14	Ann J-H, Kim S-W, Hong S-M, et al: Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung carcinoma. J Korean Med Sci. 19:529–535. 2004. View Article : Google Scholar
15	Sainsbury JRC, Nicholson S, Angus B, et al: Epidermal growth factor receptor status of histological sub-types of breast cancer. Br J Cancer. 58:458–460. 1988. View Article : Google Scholar : PubMed/NCBI
16	Yasui W, Sumiyoshi H, Hata J, et al: Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res. 48:137–141. 1988.PubMed/NCBI
17	Smith K, Fenelly JA, Neal DE, et al: Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res. 49:5810–5815. 1989.PubMed/NCBI
18	Veale D, Kerr N, Gibson GJ, et al: Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res. 49:1313–1317. 1989.PubMed/NCBI
19	Fujino S, Enokibori T, Tezuka N, et al: A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur J Cancer. 32A:2070–2074. 1996. View Article : Google Scholar : PubMed/NCBI
20	Hortobagyi GN and Santer G: Challenges and opportunities for erlotinib (tarceva). What does the future hold? Semin Oncol. 30(Suppl 7): 47–53. 2003. View Article : Google Scholar : PubMed/NCBI
21	Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasias. J Clin Oncol. 19:S32–S40. 2001.PubMed/NCBI
22	Perez-Soler R: HER1/EGFR targeting: refining the strategy. Oncologist. 9:58–67. 2004. View Article : Google Scholar : PubMed/NCBI
23	Weinstein IB: Addiction to oncogenes – the Achilles heal of cancer. Science. 297:63–64. 2002.
24	Crino L, Eberhardt W, Boyer M, et al: Erlotinib as second-line therapy in patients (PTS) with advanced non-small cell lung cancer (NSCLC) and good performance status: interim analyses from the TRUST Study. In: Abstract Book 33rd ESMO Congress; (Suppl 8): pp. 2642008
25	Groen H, Barata F, McDermott R, et al: Efficacy of erlotinib in >4000 patients (PTS) with advanced non-small cell lung cancer (NSCLC): analysis of the European subpopulation on the TRUST Study. In: Abstract Book 33rd ESMO Congress; (Suppl 8): pp. 2662008
26	Reck M, Mali P, Arrieta O, et al: Global efficacy and safety results from the TRUST study of erlotinib monotherapy in >7000 patients (PTS) with non-small cell lung cancer (NSCLC). In: Abstract Book 33rd ESMO Congress; (Suppl 8): pp. 2622008